SC 13G/A: Q32 Bio Inc.

AI Summary

SC 13G/A filing by Q32 Bio Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• arch-sch13g_18837.htm (SC 13G/A) — 64KB
• 0001072613-24-000468.txt ( ) — 65KB

(a)

Item 1(a). Name of Issuer Homology Medicines, Inc. (the "Issuer").

(b)

Item 1(b). Address of Issuer's Principal Executive Offices 1 Patriots Park, Bedford, MA 01730

(a)

Item 2(a). Name of Person Filing ARCH Venture Fund VIII, L.P. (“ARCH Venture Fund VIII”); ARCH Venture Fund VIII Overage, L.P. (“AVF VIII Overage LP”); ARCH Venture Partners VIII, L.P. (“AVP VIII LP”); ARCH Venture Partners VIII, LLC (“AVP VIII LLC”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”). The Reporting Entities and the Managing Directors collectively are referred to as the “Reporting Persons”.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence 8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

(c)

Item 2(c). Citizenship ARCH Venture Fund VIII, AVF VIII Overage LP and AVP VIII LP are limited partnerships organized under the laws of the State of Delaware. AVP VIII LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.

(d)

Item 2(d). Title of Class of Securities Common stock, par value $0.0001 per share.

(e)

Item 2(e). CUSIP Number 746964105 Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not Applicable. CUSIP No. 746964105 13G Page 3 of 5 Pages Item 4. Not Applicable. Item 5. of Five Percent or Less of a Class Each of the Reporting Persons has ceased to beneficially own five percent (5%) or more of the Issuer’s outstanding Common Stock. Item 6. of More than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification Not Applicable. CUSIP No. 746964105 13G Page 4 of 5 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: May 13, 2024 ARCH VENTURE FUND VIII, L.P. By: ARCH Venture Partners VIII, L.P. its General Partner By: ARCH Venture Partners VIII, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS VIII, L.P. By: ARCH Venture Partners VIII, LLC its General Partner By: * Keith Crandell Managing Director ARCH VENTURE PARTNERS VIII, LLC By: * Keith Crandell Managing Director ARCH VENTURE FUND VIII OVERAGE, L.P. By: ARCH Venture Partners VIII, LLC its General Partner By: * Keith Crandell Managing Director * Keith Crandell * Robert Nelsen * Clinton Bybee * By: /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact *This No. 1 to Schedule 13G for Homology Med

View Full Filing

View this SC 13G/A filing on SEC EDGAR